Gilead Sciences traded at $64.03 this Wednesday September 28th, increasing $1.40 or 2.24 percent since the previous trading session. Looking back, over the last four weeks, Gilead Sciences gained 2.53 percent. Over the last 12 months, its price fell by 9.74 percent. Looking ahead, we forecast Gilead Sciences to be priced at 60.99 by the end of this quarter and at 55.70 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
64.03
Daily Change
2.24%
Yearly
-9.74%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 143.96 2.24 1.58% 32.27%
Acorda Therapeutics 0.30 0.004 1.41% -93.71%
Agios Pharmaceuticals 29.51 0.79 2.75% -36.14%
ALKERMES 22.90 0.88 4.00% -25.91%
Alnylam Pharmaceuticals 209.34 6.73 3.32% 17.97%
Amgen 230.49 4.50 1.99% 7.25%
Biogen 274.90 77.11 38.98% -3.73%
Bluebird Bio 5.63 0.18 3.30% -70.34%
BioMarin Pharmaceutical 85.02 1.58 1.89% 10.72%
Bristol-Myers Squibb 71.66 1.30 1.85% 18.21%
Coherus Biosciences 9.70 0.30 3.19% -41.07%
Gilead Sciences 64.03 1.40 2.24% -9.74%
GlaxoSmithKline 1,341.60 25.00 1.90% -4.51%
Glaxosmithkline 29.22 0.56 1.95% -23.77%
Intercept Pharmaceuticals 16.73 0.06 0.36% 10.28%
Incyte Corp 67.56 1.12 1.69% -1.62%
J&J 166.34 1.40 0.85% 1.41%
Eli Lilly 332.48 21.38 6.87% 44.33%
Merck & Co 86.56 0.72 0.84% 15.28%
Moderna Inc 122.27 0.04 0.03% -67.73%
Neurocrine Biosciences 102.21 0.85 0.83% 8.28%
Novartis 74.82 0.43 0.58% -3.12%
Puma Biotechnology 2.35 0.08 3.52% -66.57%
Pfizer 44.29 0.20 0.45% 1.75%
PTC Therapeutics 50.88 1.48 3.00% 37.33%
Regeneron Pharmaceuticals 705.00 9.99 1.44% 16.20%
Sanofi 78.71 1.26 1.63% -5.97%
Sangamo BioSciences 5.19 0.18 3.49% -43.15%
Sarepta Therapeutics 110.30 1.97 1.82% 24.25%
Teva Pharmaceutical Industries 7.98 0.24 3.04% -20.01%
United Therapeutics 210.08 4.19 2.04% 13.25%
Vertex Pharmaceuticals 291.85 7.11 2.50% 60.16%

Indexes Price Day Year
US500 3705 58.20 1.60% -15.01%
USND 10989 159.43 1.47% -24.28%
USNDX 11438 165.88 1.47% -22.47%

Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.